Literature DB >> 10945979

The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.

M G Marcu1, A Chadli, I Bouhouche, M Catelli, L M Neckers.   

Abstract

Heat shock protein 90 (Hsp90), one of the most abundant chaperones in eukaryotes, participates in folding and stabilization of signal-transducing molecules including steroid hormone receptors and protein kinases. The amino terminus of Hsp90 contains a non-conventional nucleotide-binding site, related to the ATP-binding motif of bacterial DNA gyrase. The anti-tumor agents geldanamycin and radicicol bind specifically at this site and induce destabilization of Hsp90-dependent client proteins. We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-1, and p185(ErbB2). In the present study we used deletion/mutation analysis to identify the site of interaction of novobiocin with Hsp90, and we demonstrate that the novobiocin-binding site resides in the carboxyl terminus of the chaperone. Surprisingly, this motif also recognizes ATP, and ATP and novobiocin efficiently compete with each other for binding to this region of Hsp90. Novobiocin interferes with association of the co-chaperones Hsc70 and p23 with Hsp90. These results identify a second site on Hsp90 where the binding of small molecule inhibitors can significantly impact the function of this chaperone, and they support the hypothesis that both amino- and carboxyl-terminal domains of Hsp90 interact to modulate chaperone activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945979     DOI: 10.1074/jbc.M003701200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  139 in total

1.  Hsp90 reaches new heights. Conference on the Hsp90 chaperone machine.

Authors:  Avrom J Caplan; Sophie Jackson; David Smith
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

Review 2.  Pharmacological approaches to defining the role of chaperones in aging and prostate cancer progression.

Authors:  Sarah A Harvey; Keith O Jensen; Lynne W Elmore; Shawn E Holt
Journal:  Cell Stress Chaperones       Date:  2002-04       Impact factor: 3.667

3.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 4.  GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum.

Authors:  Michal Marzec; Davide Eletto; Yair Argon
Journal:  Biochim Biophys Acta       Date:  2011-11-03

5.  Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells.

Authors:  Takashi Imai; Yu Kato; Chiaki Kajiwara; Shusaku Mizukami; Ikuo Ishige; Tomoko Ichiyanagi; Masaki Hikida; Ji-Yang Wang; Heiichiro Udono
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

6.  The second metal-binding site of 70 kDa heat-shock protein is essential for ADP binding, ATP hydrolysis and ATP synthesis.

Authors:  Xueji Wu; Mihiro Yano; Hiroyo Washida; Hiroshi Kido
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

7.  Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.

Authors:  Steven Bellon; Jonathan D Parsons; Yunyi Wei; Koto Hayakawa; Lora L Swenson; Paul S Charifson; Judith A Lippke; Robert Aldape; Christian H Gross
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 8.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

9.  Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.

Authors:  Sanil Bhatia; Daniela Diedrich; Benedikt Frieg; Heinz Ahlert; Stefan Stein; Bertan Bopp; Franziska Lang; Tao Zang; Tobias Kröger; Thomas Ernst; Gesine Kögler; Andreas Krieg; Steffen Lüdeke; Hana Kunkel; Ana J Rodrigues Moita; Matthias U Kassack; Viktoria Marquardt; Friederike V Opitz; Marina Oldenburg; Marc Remke; Florian Babor; Manuel Grez; Andreas Hochhaus; Arndt Borkhardt; Georg Groth; Luitgard Nagel-Steger; Joachim Jose; Thomas Kurz; Holger Gohlke; Finn K Hansen; Julia Hauer
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

10.  Exploiting polarity and chirality to probe the Hsp90 C-terminus.

Authors:  Leah K Forsberg; Rachel E Davis; Virangika K Wimalasena; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2018-04-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.